ReviewMolecular oncology2015
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.
Review in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Study designs for clinical trials applied to personalised medicine: a scoping review.BMJ open · 2022Article
- Towards a cancer mission in Horizon Europe: recommendations.Molecular oncology · 2020Article
- Genomics and the History of Precision Oncology.Surgical oncology clinics of North America · 2020Review
- New clinical trial designs in the era of precision medicine.Molecular oncology · 2019Review
- Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells.Oxidative medicine and cellular longevity · 2019Article
- The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.Expert review of anticancer therapy · 2018Review
- Circulating Tumor DNA as Biomarkers for Cancer Detection.Genomics, proteomics & bioinformatics · 2017Review
- Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.Nature reviews. Cancer · 2017Review
- A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.Genome medicine · 2016Article
- OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine.Applied & translational genomics · 2015Article
- Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.Molecular oncology · 2015Review
- Prioritizing therapeutic targets using patient-derived xenograft models.Biochimica et biophysica acta · 2015Review
- Article
- From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.Cancer journal (Sudbury, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new age of Precision Cancer Medicine, with specific biomarkers being used to direct targeted agents, generally concerns only a subset of patients within a certain histopathologically defined tumor type. This paradigm is challenged by the need to perform widespread molecular screening in certified laboratories, with results available to clinicians within reasonable timeframe. Tumor heterogeneity and clonal evolution must be considered in the decision making process. Adaptive and innovative clinical trial designs exploring predictive algorithms and reconsideration of traditional efficacy endpoints are required to rapidly translate scientific discoveries into patient care. Furthermore, international collaboration in cancer research and open discussions on the availability of investigational agents will likely redefine the drug development and approval process in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.